T 1638/14 (Gefitinib resistant cancer/WYETH) of 01.12.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T163814.20201201
- Date of decision
- 1 December 2020
- Case number
- T 1638/14
- Petition for review of
- -
- Application number
- 06720163.2
- IPC class
- A61K 38/17A61P 35/00A61K 31/4706
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- METHOD FOR TREATING GEFITINIB RESISTANT CANCER
- Applicant name
- THE GENERAL HOSPITAL CORPORATION
Wyeth LLC - Opponent name
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- Board
- 3.3.01
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 99(1) (2007)European Patent Convention R 139 (2007)European Patent Convention R 76(2)(a) (2007)European Patent Convention R 77(1) (2009)
- Keywords
- Admissibility of opposition (no)
Admissibility of opposition - identification of the opponent
Correction of error (no)
Correction of error - late request and no evidence of true intention - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The opposition is rejected as inadmissible.